Last10K.com

Bristol Myers Squibb Co (BMY) SEC Filing 10-K Annual Report for the fiscal year ending Saturday, December 31, 2022

SEC Filings

BMY Valuations

Intrinsic Value
Financial Stability
Financial Ratios
Insider Trades
Manager Portfolios
Notifications

BMY Annual Reports

  • 10-K Annual Report February 2023
    • 10-K Annual Report February 2022
    10-K Annual Report February 2021
    10-K Annual Report February 2020
    10-K Annual Report February 2019
    10-K Annual Report February 2018
    10-K Annual Report February 2017
    10-K Annual Report February 2016
    10-K Annual Report February 2015

BMY Quarterly Reports

BMY Corporate News

Bristol Myers Squibb Co

HISTORY TOOLS
CIK: 14272 Ticker: BMY
Exhibit 99.1
bmslogo2021.jpg

Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2022
•Reports Fourth Quarter Revenues of $11.4 Billion; Full-Year Revenues of $46.2 Billion
◦Fourth Quarter Revenues from In-Line Products and New Product Portfolio were $9.0 Billion, an Increase of 7%, or 12% When Adjusted for Foreign Exchange
◦Full-Year Revenues from In-Line Products and New Product Portfolio were $35.4 Billion, an Increase of 9%, or 13% When Adjusted for Foreign Exchange
•Posts Fourth Quarter GAAP EPS of $0.95 and Non-GAAP EPS of $1.82; Includes Net Impact of ($0.01) Per Share for GAAP and Non-GAAP EPS Due to Acquired IPRD Charges and Licensing Income
•Reports Full-Year GAAP EPS of $2.95 and Non-GAAP EPS of $7.70; Includes Net Impact of ($0.24) Per Share for GAAP and Non-GAAP EPS Due to Acquired IPRD Charges and Licensing Income
•Provides GAAP and Non-GAAP Financial Guidance for 2023 Reflecting Continued Revenue and Earnings Growth

(NEW YORK, February 2, 2023) –
 Bristol Myers Squibb (NYSE:BMY) today reports results for the fourth quarter and full year of 2022, which reflect robust growth of the in-line and new product portfolios, driven by strong commercial execution and continued progress of the company's pipeline.

“2022 was a successful year for our company, one of significant clinical and regulatory achievements that broadened our product portfolio and advanced our pipeline,” said Giovanni Caforio, M.D., board chair and chief executive officer, Bristol Myers Squibb. “We are especially proud to have launched three first-in-class medicines that address serious unmet medical needs for patients. Our financial strength, talented workforce and proven ability to execute will enable us to continue to progress our pipeline and invest in future sources of innovation. With a younger and more diversified portfolio, promising mid-to-late stage registrational assets and a deep early-stage pipeline, I am confident that the company is well positioned for multiple waves of innovation that will support long-term growth.”

1

The following information was filed by Bristol Myers Squibb Co (BMY) on Thursday, February 2, 2023 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Bristol Myers Squibb Co's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Bristol Myers Squibb Co.

Continue

Assess how Bristol Myers Squibb Co's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Bristol Myers Squibb Co's Definitive Proxy Statement (Form DEF 14A) filed after their 2023 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Rating

Learn More
Bullish Bearish Neutral
Filter Sentiment:
All
Positive
Negative
Filter Category:
All
Revenue
Legal
Financial
M & A
Other
Filter Subcategory:
All
Product
Cash Flow
Expense
Shares
Debt
Income
Dividend
Geography
Other
Inside Bristol Myers Squibb Co's 10-K Annual Report:

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Audit Information
Cover Page
Consolidated Balance Sheets
Consolidated Balance Sheets (Parenthetical)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Comprehensive Income/(Loss)
Consolidated Statements Of Earnings
Accounting Policies (Tables)
Accounting Policies And Recently Issued Accounting Standards
Accounting Policies And Recently Issued Accounting Standards (Details)
Accounting Policies And Recently Issued Accounting Standards (Policies)
Accounting Policies And Recently Issued Accounting Standards - Acquired Iprd By Type Of Transaction (Details)
Acquisitions, Divestitures, Licensing And Other Arrangements
Acquisitions, Divestitures, Licensing And Other Arrangements (Tables)
Acquisitions, Divestitures, Licensing And Other Arrangements - Additional Information (Details)
Acquisitions, Divestitures, Licensing And Other Arrangements - Divestitures (Details)
Acquisitions, Divestitures, Licensing And Other Arrangements - Licensing And Other Arrangements (Details)
Acquisitions, Divestitures, Licensing And Other Arrangements - Schedule Of Consideration Transferred (Details)
Acquisitions, Divestitures, Licensing And Other Arrangements - Schedule Of Recognized Identified Assets Acquired And Liabilities Assumed (Details)
Alliances
Alliances (Tables)
Alliances - Financial Information Pertaining To Alliances (2Seventy Bio) (Details)
Alliances - Financial Information Pertaining To Alliances (Bridgebio) (Details)
Alliances - Financial Information Pertaining To Alliances (Eisai) (Details)
Alliances - Financial Information Pertaining To Alliances (Nektar) (Details)
Alliances - Financial Information Pertaining To Alliances (Ono) (Details)
Alliances - Financial Information Pertaining To Alliances (Pfizer) (Details)
Alliances - Financial Information Pertaining To Alliances (Total) (Details)
Earnings/(Loss) Per Share
Earnings/(Loss) Per Share (Details)
Earnings/(Loss) Per Share (Tables)
Employee Stock Benefit Plans
Employee Stock Benefit Plans (Tables)
Employee Stock Benefit Plans - Additional Information (Details)
Employee Stock Benefit Plans - Stock Based Compensation Expense (Details)
Employee Stock Benefit Plans - Summary Of Significant Outstanding And Exercisable Options (Details)
Employee Stock Benefit Plans - Summary Of Stock Compensation Activity (Details)
Equity
Equity (Tables)
Equity - Additional Information (Details)
Equity - Schedule Of Accumulated Other Comprehensive Income (Loss) (Details)
Equity - Schedule Of Comprehensive Income (Loss) (Details)
Equity - Schedule Of Stockholders Equity (Details)
Financial Instruments And Fair Value Measurements
Financial Instruments And Fair Value Measurements (Tables)
Financial Instruments And Fair Value Measurements - Additional Information (Details)
Financial Instruments And Fair Value Measurements - Available-For-Sale Securities (Details)
Financial Instruments And Fair Value Measurements - Derivative Instruments, Gain (Loss) (Details)
Financial Instruments And Fair Value Measurements - Gain/(Loss) On Hedging Activity (Details)
Financial Instruments And Fair Value Measurements - Schedule Of Derivatives And Fair Value (Details)
Financial Instruments And Fair Value Measurements - Schedule Of Equity Investments (Details)
Financial Instruments And Fair Value Measurements - Schedule Of Financial Assets And Liabilities Measured At Fair Value (Details)
Financial Instruments And Fair Value Measurements - Summary Of Equity Investments Carrying Amount (Details)
Financing Arrangements
Financing Arrangements (Tables)
Financing Arrangements - Additional Information (Details)
Financing Arrangements - Long-Term Debt (Details)
Financing Arrangements - Short-Term Debt (Details)
Goodwill And Other Intangible Assets
Goodwill And Other Intangible Assets (Tables)
Goodwill And Other Intangible Assets - Additional Information (Details)
Goodwill And Other Intangible Assets - Schedule Of Goodwill (Details)
Goodwill And Other Intangible Assets - Schedule Of Intangible Assets (Details)
Income Taxes
Income Taxes (Tables)
Income Taxes - Additional Information (Details)
Income Taxes - Schedule Of Deferred Tax Assets And Liabilities (Details)
Income Taxes - Schedule Of Effective Income Tax Rate Reconciliation (Details)
Income Taxes - Schedule Of Provision For Income Taxes (Details)
Income Taxes - Summary Of Income Tax Contingencies (Details)
Income Taxes - Summary Of Income Tax Examinations (Details)
Income Taxes - Summary Of Valuation Allowance (Details)
Inventories
Inventories (Details)
Inventories (Tables)
Leases
Leases (Tables)
Leases - Additional Information (Details)
Leases - Balance Sheet Information Related To Leases (Details)
Leases - Summary Of Components Of Lease Expense (Details)
Leases - Summary Of Operating Lease Maturity (Details)
Leases - Supplemental Balance Sheet Information Related To Leases (Details)
Legal Proceedings And Contingencies
Legal Proceedings And Contingencies (Details)
Other (Income)/Expense, Net
Other (Income)/Expense, Net (Tables)
Other (Income)/Expense, Net - Schedule Of Other Income Expense (Details)
Property, Plant And Equipment
Property, Plant And Equipment (Details)
Property, Plant And Equipment (Tables)
Receivables
Receivables (Tables)
Receivables - Additional Information (Details)
Receivables - Receivables Allowance (Details)
Receivables - Schedule Of Accounts, Notes, Loans And Financing Receivable (Details)
Restructuring
Restructuring (Tables)
Restructuring - Additional Information (Details)
Restructuring - Schedule Of Restructuring And Related Costs (Details)
Restructuring - Schedule Of Restructuring Reserve By Type Of Cost (Details)
Retirement Benefits
Retirement Benefits (Tables)
Retirement Benefits - Actuarial Assumptions (Details)
Retirement Benefits - Additional Information (Details)
Retirement Benefits - Fair Value Of Pension Plan Assets By Asset Category (Details)
Retirement Benefits - Schedule Of Accumulated And Projected Benefit Obligation In Excess Of Fair Value Of Plan Assets (Details)
Retirement Benefits - Schedule Of Defined Benefit Obligations And Assets (Details)
Revenue
Revenue (Tables)
Revenue - Additional Information (Details)
Revenue - Disaggregation Of Revenue (Details)
Revenue - Disaggregation Of Revenue By Product And Region (Details)
Revenue - Reconciliation Of Gross Product Sales To Net Product Sales (Details)
Revenue - Schedule Of Revenue By Major Customers (Details)
Supplemental Financial Information
Supplemental Financial Information (Tables)
Supplemental Financial Information - Other Current Assets (Details)
Supplemental Financial Information - Other Current Liabilities (Details)
Supplemental Financial Information - Other Non-Current Assets (Details)
Supplemental Financial Information - Other Non-Current Liabilities (Details)
Ticker: BMY
CIK: 14272
Form Type: 10-K Annual Report
Accession Number: 0000014272-23-000046
Submitted to the SEC: Tue Feb 14 2023 4:24:27 PM EST
Accepted by the SEC: Tue Feb 14 2023
Period: Saturday, December 31, 2022
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media
SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/bmy/0000014272-23-000046.htm